Observer-blind Monocentric Study in Adults Aged Between 18-60 Years to Evaluate Reactogenicity and Immunogenicity of 1 and 2 Administrations of Pandemic Monovalent Influenza Vaccines Administered at Different Antigen Doses and Adjuvanted or Not
Latest Information Update: 04 Jul 2023
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary) ; Adjuvants
- Indications Influenza A virus H5N1 subtype; Influenza A virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 18 Aug 2007 Results have been reported.
- 27 Jan 2007 Status change
- 12 Oct 2006 Status change